Patents Examined by Amanda Haney
  • Biomarkers for post-traumatic stress states
    Patent number: 10428384
    Abstract: The present invention relates generally to the detection or diagnosis of post-traumatic stress states in a subject, and provides methods, reagents, and kits useful for this purpose. Provided herein are biomarkers that are indicative of and/or diagnostic of post-traumatic stress states including PTSD.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: October 1, 2019
    Assignee: Northwestern University
    Inventor: Eva E. Redei
  • miRNA biomarkers for radiation biodosimetry
    Patent number: 10407726
    Abstract: Disclosed herein are miRNA biomarkers and methods for measuring exposure of a mammalian subject to ionizing radiation using a cell-free biological sample. Also disclosed are dosimeters and methods for triaging and treating a subject exposed to ionizing radiation.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: September 10, 2019
    Assignee: Ohio State Innovation Foundation
    Inventors: Naduparambil Jacob, Arnab Chakravarti
  • Methods employing circulating DNA and miRNA as biomarkers for female infertility
    Patent number: 10400282
    Abstract: The present invention relates generally to the fields of reproductive medicine. More specifically, the present invention relates to methods for determining the ovarian reserve and ovarian function by determining the level of cell-free nucleic acids or the level of a miRNA species selected from miR_30_a or miR_140 or let_7_b or miR_191 or miR_320_a or miR_21 or miR_30_d or miR_574_3p. The method may also be used in predicting the efficacy of controlled ovarian hyperstimulation.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: September 3, 2019
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉET DE LA RECHERCHE MÉDICALE), UNIVERSITE DE MONTPELLIER, CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER
    Inventors: Samir Hamamah, Sabine Traver, Elodie Scalici
  • Compositions and methods for identifying altered effectiveness of beta blocker therapy
    Patent number: 10378056
    Abstract: The present invention provides a method of identifying a human subject as having an increased risk of altered effectiveness of beta blocker therapy, comprising detecting in the subject one or more single nucleotide polymorphism associated with increased risk of altered effectiveness of beta blocker therapy.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: August 13, 2019
    Assignee: Duke University
    Inventors: Miklos D. Kertai, Mihai V. Podgoreanu, Joseph P. Mathew, Yi-Ju Li
  • ZNF365/ZFP365 biomarker predictive of anti-cancer response
    Patent number: 10378060
    Abstract: The present invention is based on the identification of novel biomarkers predictive of response to anti-cancer therapies.
    Type: Grant
    Filed: October 11, 2012
    Date of Patent: August 13, 2019
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Ronald A. DePinho, Ji-Hye Paik
  • Process for separation of prokaryotic DNA from eukaryotic DNA in a whole blood sample
    Patent number: 10358640
    Abstract: A process for separating prokaryotic DNA from eukaryotic DNA in a whole blood sample infected by pathogen is provided. The process includes extracting prokaryotic and eukaryotic DNA from the whole blood sample, contacting the prokaryotic DNA in the whole blood sample with a motif that specifically binds to the prokaryotic DNA, and generating a bound pair. The process also includes separating the bound pair. The whole blood sample is transfected with bacteriophages genetically modified to contain a defined DNA sequence having a selectable marker DNA. The DNA sequence integrates into the prokaryotic DNA, and the motif is an oligonucleotide specific to the defined DNA sequence in the engineered bacteriophages.
    Type: Grant
    Filed: August 18, 2015
    Date of Patent: July 23, 2019
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Subhadra Rukmini Jayaraman, Ramya Vutukuru
  • Methods and kits to predict therapeutic outcome of BTK inhibitors
    Patent number: 10322127
    Abstract: Methods of tests that assess the expression of DPC4 (SMAD4) to identify subjects with pancreatic cancer that are likely or unlikely to respond to treatment with BTK inhibitors; methods of treating subjects based on identification of the subjects as likely to respond to treatment with BTK inhibitors; therapeutic targets for cancers, particularly cancers with inactivated DPC4 gene or protein; methods of screening of new therapeutic agents using the target; pharmaceutical composition comprising BTK inhibitors, such as PCI-32765 or derivatives thereof, for cancer treatment; and kits that facilitate the performance of the methods are disclosed.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: June 18, 2019
    Assignee: The Translational Genomics Research Institute
    Inventors: Haiyong Han, Daniel Von Hoff, Caroline H. Diep, Hongwei Yin
  • Methods and biomarkers for analysis of colorectal cancer
    Patent number: 10308980
    Abstract: The present invention relates to methods and biomarkers (e.g., gene expression biomarkers) for detection of colorectal cancer in biological samples (e.g., tissue samples, biopsy samples, stool samples, blood samples, plasma samples, serum samples). In some embodiments, methods and biomarkers of the present invention find use in detection of colon cancer and in providing a prognosis to colorectal cancer patients.
    Type: Grant
    Filed: November 5, 2012
    Date of Patent: June 4, 2019
    Assignee: OSLO UNIVERSITETSSYKEHUS HF
    Inventors: Ragnhild A. Lothe, Trude Holmeide Agesen, Anita Sveen, Guro Elisabeth Lind, Arild Nesbakken, Rolf Inge Skotheim
  • Biomarker FOXF2 for gastric cancer
    Patent number: 10294530
    Abstract: The present invention provides a method for diagnosing and determining prognosis of gastric cancer in a subject by detecting suppressed expression of the FOXF2 gene, which in some cases is due to elevated methylation level in the genomic sequence of this gene. A kit and device useful for such a method are also provided. In addition, the present invention provides a method for treating gastric cancer by increasing FOXF2 gene expression or activity.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: May 21, 2019
    Assignee: The Chinese University of Hong Kong
    Inventors: Jun Yu, Joseph Jao Yiu Sung
  • Systems and methods for genotyping seed components
    Patent number: 10280472
    Abstract: Methods for obtaining genetic material from plant embryos while preserving their viability as well as methods for performing a molecular analysis of plant embryos, particularly with small quantities of genetic material by collecting shed cellular material from one or more plant embryos; obtaining DNA from the shed cellular material; performing a molecular analysis of the DNA; and germinating at least one of the one or more plant embryos. A further extension includes determining whether to germinate and grow the embryo or to discard the embryo based on its genotype as part of a breeding process. Also provided are methods of genotyping embryos using embryo shed cellular material contained in or on agar and methods of analyzing plant embryonic tissue derived from microspores.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: May 7, 2019
    Assignee: PIONEER HI-BRED INTERNATIONAL, INC.
    Inventors: Randal Arnold, Matthew Paul Cope, Justin Andrew Schares, Yue Yun
  • FIG4 gene mutations in neurodegeneration
    Patent number: 10260100
    Abstract: The present invention relates to neuropathy, in particular to mutations in the FIG4 gene. The present invention also provides assays for the detection of variant FIG4 alleles, and assays for detecting FIG4 polymorphisms and mutations associated with disease states.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: April 16, 2019
    Assignees: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, BAYLOR COLLEGE OF MEDICINE
    Inventors: Miriam Meisler, James R. Lupski, Clement Chow
  • Method for using gene expression to determine prognosis of prostate cancer
    Patent number: 10260104
    Abstract: The present disclosure includes assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for the patient, and likelihood that the patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: April 16, 2019
    Assignee: Genomic Health, Inc.
    Inventors: Steven Shak, Frederick L. Baehner, Tara Maddala, Mark Lee, Robert J. Pelham, Wayne Cowens, Diana Cherbavaz, Michael C. Kiefer, Michael Crager, Audrey Goddard, Joffre B. Baker
  • Methods and devices for bone infection treatment selection
    Patent number: 10258665
    Abstract: Disclosed are methods for identifying patients at increased risk of developing disseminated staphylococcal infection, which includes the steps of determining that the patient has a mutation in one or more genes selected from a MPDZ network gene, a CGNL1 network gene, a PRKRIR network gene, a MED26 network gene, a tight junction protein gene, or an immune modulator gene; and treating the patient for disseminated staphylococcal infection. Also disclosed are solid substrates and/or assays useful for carrying out the disclosed methods.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: April 16, 2019
    Assignee: Children's Hospital Medical Center
    Inventors: Bruce J. Aronow, John B. Harley, Margaret Hostetter, Kenneth Kaufman
  • Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors
    Patent number: 10238649
    Abstract: A method for treating patients afflicted with cancer, wherein the patients are treated with a compound including tyrosine kinase inhibitor, mast cell inhibitor or c-Kit inhibitor, in particular masitinib, optionally in combination with at least one antineoplastic agent. The tyrosine kinase inhibitor, mast cell inhibitor or c-Kit inhibitor, and the optional at least one antineoplastic agent, are administered in a dosage regimen that includes a therapeutically effective amount. Also described are methods for predicting therapeutic response to the treatment in a given patient and therefore identification of applicable patient subpopulations based upon these predictor factors; sometimes referred to as biomarkers. One method is based upon the clinical marker of pain intensity.
    Type: Grant
    Filed: October 4, 2013
    Date of Patent: March 26, 2019
    Assignee: AB SCIENCE
    Inventors: Alain Moussy, Jean-Pierre Kinet
  • Biomarkers predictive of predisposition to depression and response to treatment
    Patent number: 10233501
    Abstract: The present invention relates generally to the identification of subjects with a predisposition to recurrent depression, predicting a subject's responsiveness to therapy, and determining whether a subject has remitted from depression following therapy. In particular, provided herein are biomarkers, methods, and kits for such uses.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: March 19, 2019
    Assignee: Northwestern University
    Inventor: Eva E. Redei
  • Mutations associated with cystic fibrosis
    Patent number: 10233499
    Abstract: The present invention provides novel mutations identified in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that can be used for a more accurate diagnosis of cystic fibrosis (CF) and CF related disorders. Methods for testing a sample obtained from a subject to determine the presence of one or more mutations in the CFTR gene are provided wherein the presence of one or more mutations indicates that the subject has CF or a CF related disorder, or is a carrier of a CFTR mutation.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: March 19, 2019
    Assignee: Laboratory Corporation of America Holdings
    Inventors: Elizabeth Rohlfs, Deborah Alexa Sirko-Osadsa, Lynne Rosenblum, Narasimhan Nagan, Zhaoqing Zhou, Ruth Heim
  • Gene expression based biomarker system for irritable bowel syndrome (IBS) diagnosis
    Patent number: 10227651
    Abstract: We have identified a suite of genes in a limited number of human colonic tissue samples with expression patterns that correlate with whether an individual is experiencing symptoms of Irritable Bowel Syndrome (IBS) (FIG. 2). Interestingly, in the efforts to screen for genes that might be used as biomarkers for IBS, it was found that no single gene could be used for this purpose. Instead, when examining the entire dataset, there exist signature gene expression patterns (e.g., fingerprints or biosignatures) of IBS that have use as a diagnostic tool for IBS.
    Type: Grant
    Filed: February 24, 2015
    Date of Patent: March 12, 2019
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Todd Sandrin, Peter Jurutka
  • Genetic markers for predicting responsiveness to FPG-18 compound
    Patent number: 10221456
    Abstract: This application is directed to the use of biomarkers for predicting the sensitivity to treatment with an FGF-18 compound of a patient having a cartilage disorder, such as osteoarthritis, cartilage injury, fractures affecting joint cartilage or surgical procedures with impact on joint cartilage (e.g., microfracture), in order to reduce the risk of adverse events and increase the overall benefit after therapy.
    Type: Grant
    Filed: August 5, 2013
    Date of Patent: March 5, 2019
    Assignee: MERCK PATENT GMBH
    Inventors: Christoph Hubertus Ladel, Alix Anne Simone Berton, Armand Valsesia, Pierre Jacques Farmer
  • Method for analyzing maternal DNA in large plant populations
    Patent number: 10174370
    Abstract: The present invention relates to a non-destructive method for analyzing maternal DNA of a seed. In this method the DNA may be dislodged from the seed coat surface and may be used to collect information on the genome of the maternal parent of the seed. Also, the present invention provides a high throughput DNA analysis system for large plant populations.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: January 8, 2019
    Assignee: RIJK ZWAAN ZAADTEELT EN ZAADHANDEL B.V.
    Inventor: Cornelis Maria Petrus Van Dun
  • Methods and systems for predicting whether a subject has a cervical intraepithelial neoplasia (CIN) lesion from a suspension sample of cervical cells
    Patent number: 10167526
    Abstract: Methods of predicting whether a subject has a cervical intraepithelial neoplasia (CIN) lesion are provided. Aspects of the methods include obtaining both morphometric and biomarker data from a liquid cervical cellular sample and then using both types of data to predict whether the subject has a CIN lesion. Also provided are systems that find use in practicing the methods. The methods and systems find use in a variety of applications, including cervical cancer screening applications.
    Type: Grant
    Filed: May 19, 2015
    Date of Patent: January 1, 2019
    Assignee: IncellDx, Inc.
    Inventor: Bruce K. Patterson